Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This year tags : Disease save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.16 1.35% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CMMB | News | $0.629 6.61% 6.2% 30K
|
Manufacturing
|
| O: -3.38%
H: 0.0%
C: 0.0%
ccl24 disease association publication sclerosis
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 0.0%
H: 7.32%
C: -1.95%
disease neurology system meeting parkinson’s therapeutics
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $358.65 -2.06% -2.11% 240K
|
Health Technology
|
| O: -5.0%
H: 4.19%
C: 2.86%
disease vyvgart for
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.51 -2.8% -2.88% 260K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN | News P 0 d | $2.005 -4.07% -4.24% 990K
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.6 -3.77% -3.91% 1.1M
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $2.97 4.58% 4.38% 150K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
conference disease meeting week
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.96 1.02% 6.6K
|
Finance and Insurance
|
| O: 1.87%
H: 4.59%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.41 4.44% 4.26% 2.3M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CRL | $227.55 -1.1% 0.0% 710K
|
Commercial Services
|
| O: 0.93%
H: 0.36%
C: -0.05%
rare disease collaboration therapeutics therapy
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Published: 2024-04-09 (Crawled : 12:30) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 8.14%
H: 3.71%
C: -7.53%
disease order diagnostics neurodegenerative
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $19.415 -3.17% -3.27% 220K
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 5.7%
H: 11.98%
C: 7.78%
disease risk meeting heart cardiology
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.